Published Date: 26 Apr 2023
Psilocybin, LSD, and MDMA are psychedelic drugs that may significantly lessen the severity of depression and anxiety symptoms in people with advanced cancer.
Read Full NewsIn a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?
New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.
A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.
A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.
1.
Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most
2.
The Truth About Apple AirPods
3.
Too Many Kids With Sickle Cell Disease Aren't Getting Appropriate Preventive Care
4.
Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.
5.
Investigating the Relationship Between GERD and Anxiety/Depression.
1.
Understanding the HAS-BLED Score: What It Is and Why It Matters
2.
Unlocking a New Era in Bladder Cancer Treatment: A Review of the TAR-200 Intravesical Drug Delivery System
3.
Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide
4.
Everything You Need to Know About the Latest Hyponatremia Algorithm
5.
Understanding SVR Normal Range: A Guide to Achieving Optimal Health
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
3.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
4.
Updates on the First Line Management of ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation